Zafgen, Inc. is a biopharmaceutical company. The company has a market cap of $171.95 million. The Firm is engaged in improving the health and well-being of patients affected by Obesity and complex metabolic disorders. It currently has negative Earnings. The Company’s lead product candidate, Beloranib is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in two rare diseases, Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity, and severe obesity.
The post Analysts See Rise of Zafgen Inc (ZFGN) Earnings Per Share appeared first on Octafinance.